Pharmacometric Modeling of Liver Metastases' Diameter, Volume, and Density and Their Relation to Clinical Outcome in Imatinib-Treated Patients With Gastrointestinal Stromal Tumors.
Autor: | Schindler E; Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden., Krishnan SM; Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden., Mathijssen R; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Ruggiero A; Department of Radiology, Papworth Hospital NHS Foundation Trust, Cambridge University Health Partners, Cambridge, CB23 3RE, United Kingdom., Schiavon G; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Friberg LE; Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden. |
---|---|
Jazyk: | angličtina |
Zdroj: | CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2017 Jul; Vol. 6 (7), pp. 449-457. Date of Electronic Publication: 2017 May 30. |
DOI: | 10.1002/psp4.12195 |
Abstrakt: | Three-dimensional and density-based tumor metrics have been suggested to better discriminate tumor response to treatment than unidimensional metrics, particularly for tumors exhibiting nonuniform size changes. In the developed pharmacometric modeling framework based on data from 77 imatinib-treated gastrointestinal patients, the time-courses of liver metastases' maximum transaxial diameters, software-calculated actual volumes (V (© 2017 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.) |
Databáze: | MEDLINE |
Externí odkaz: |